GH Stock Guardant Health, Inc.
US · NasdaqGSLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Blood-based cancer detection growth and AI-enabled diagnostics provide substantial long-term expansion potential.
Future value: $201.64 (+19.26%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Positive attention around blood-based cancer detection innovation.
- ▸Above 50-day MA (+0.67%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (82.1% of range) — strength
Is GH a buy right now?
Trend: GH is trading above the 50-day average (+0.67%), RSI 38 — neutral momentum, with a 3-month return of +16.23%.
Valuation & quality: Guardant Health, Inc. trades on forward P/E -456.9; fundamentals show net margin -38.3%, revenue growth 44.3% year on year.
Analyst consensus: 25 analysts have a mean 12-month price target of $201.64 (+16.4% vs the last close; range $105.00 – $240.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Blood-based cancer detection growth and AI-enabled diagnostics provide substantial long-term expansion potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -1.60% | -5.70% | +48.90% | +15.70% | +8.00% | -1.80% | +12.20% | -5.20% |
Fundamentals
Analyst price target
Technical signals
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 2,490 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.